Studies reported in previous decades have illustrated that DTYMK is likely to have a function in determining a grim prognosis in patients with non-small cell lung cancer (NSCLC), and it might be a viable treatment target for these patients. The gene discussed is DTYMK; the disease is non-small cell lung carcinoma.